About
About KPC Pharmaceuticals, Inc
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, antibiotics, immunosuppressive, oral products, injections, and other products, as well as engages in the wholesale and retail of medicines and equipment. The company offers products in the field of cardiovascular and cerebrovascular, orthopedics series, antimalarial, gynecology, digestive system, and others treatments. It offers its products under Luotai, Tianxuanqing, Artemedine, Artem, and Arco brands. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. KPC Pharmaceuticals,Inc. was founded in 1951 and is based in Kunming, the People's Republic of China.
Visit company website
5 years, 5 months ago
KPC Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 13.9% above its 200 day moving average.
From a valuation standpoint, the stock is 91.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.8.
KPC Pharmaceuticals, Inc's total revenue sank by 2.6% to $2B since the same quarter in the previous year.
Its net income has increased by 12.0% to $106M since the same quarter in the previous year.
Finally, its free cash flow grew by 131.7% to $216M since the same quarter in the previous year.
Based on the above factors, KPC Pharmaceuticals, Inc gets an overall score of 4/5.